ASTRAZENECA PHARMACEUTICALS LP: 1st-line Tagrisso demonstrates sustained benefit post progression in patients with EGFR-mutated non-small cell lung cancer
The unprecedented progression-free survival benefit for 1st-line Tagrisso demonstrated in the FLAURA trial is preserved through subsequent lines of therapy Read More »